SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) (the “Company” or “Ligand”) today announced that it has completed the acquisition of Pharmacopeia, Inc. (“Pharmacopeia”), following approval of the transaction by Pharmacopeia stockholders earlier today. The acquisition, announced on September 24, 2008, is an important element of Ligand’s strategy for creating shareholder value. Ligand stockholders are expected to gain access to numerous royalty partnerships, additional pipeline assets, drug discovery resources, cash and net operating loss (NOL) tax assets.
